nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—TNF—atopic dermatitis	0.451	1	CbGaD
Pomalidomide—PTGS2—Triamcinolone—atopic dermatitis	0.0461	0.121	CbGbCtD
Pomalidomide—PTGS2—Betamethasone—atopic dermatitis	0.0396	0.104	CbGbCtD
Pomalidomide—CYP3A4—Pimecrolimus—atopic dermatitis	0.0302	0.0793	CbGbCtD
Pomalidomide—ABCB1—Tacrolimus—atopic dermatitis	0.03	0.0787	CbGbCtD
Pomalidomide—CYP1A2—Diphenhydramine—atopic dermatitis	0.0251	0.0659	CbGbCtD
Pomalidomide—PTGS2—Dexamethasone—atopic dermatitis	0.023	0.0604	CbGbCtD
Pomalidomide—ABCB1—Loratadine—atopic dermatitis	0.0219	0.0576	CbGbCtD
Pomalidomide—ABCB1—Methylprednisolone—atopic dermatitis	0.0201	0.0527	CbGbCtD
Pomalidomide—CYP3A4—Tacrolimus—atopic dermatitis	0.018	0.0472	CbGbCtD
Pomalidomide—CYP3A4—Loratadine—atopic dermatitis	0.0131	0.0345	CbGbCtD
Pomalidomide—ABCB1—Betamethasone—atopic dermatitis	0.013	0.0343	CbGbCtD
Pomalidomide—ABCB1—Prednisolone—atopic dermatitis	0.0129	0.0338	CbGbCtD
Pomalidomide—ABCB1—Hydrocortisone—atopic dermatitis	0.0122	0.0321	CbGbCtD
Pomalidomide—ABCB1—Prednisone—atopic dermatitis	0.0122	0.0319	CbGbCtD
Pomalidomide—CYP3A4—Methylprednisolone—atopic dermatitis	0.012	0.0316	CbGbCtD
Pomalidomide—CYP3A4—Triamcinolone—atopic dermatitis	0.00911	0.0239	CbGbCtD
Pomalidomide—CYP3A4—Betamethasone—atopic dermatitis	0.00782	0.0205	CbGbCtD
Pomalidomide—CYP3A4—Prednisolone—atopic dermatitis	0.00771	0.0203	CbGbCtD
Pomalidomide—ABCB1—Dexamethasone—atopic dermatitis	0.00759	0.0199	CbGbCtD
Pomalidomide—CYP3A4—Hydrocortisone—atopic dermatitis	0.00731	0.0192	CbGbCtD
Pomalidomide—CYP3A4—Prednisone—atopic dermatitis	0.00729	0.0191	CbGbCtD
Pomalidomide—CYP3A4—Dexamethasone—atopic dermatitis	0.00455	0.0119	CbGbCtD
Pomalidomide—TNF—IL23-mediated signaling events—IL18R1—atopic dermatitis	0.00217	0.0465	CbGpPWpGaD
Pomalidomide—Thalidomide—TNF—atopic dermatitis	0.00186	1	CrCbGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—RELB—atopic dermatitis	0.00148	0.0319	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL15—atopic dermatitis	0.00116	0.0249	CbGpPWpGaD
Pomalidomide—TNF—Cellular roles of Anthrax toxin—CASP1—atopic dermatitis	0.000867	0.0186	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL13—atopic dermatitis	0.000815	0.0175	CbGpPWpGaD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—CABIN1—atopic dermatitis	0.000796	0.0171	CbGpPWpGaD
Pomalidomide—TNF—IL27-mediated signaling events—IL17A—atopic dermatitis	0.000773	0.0166	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL5—atopic dermatitis	0.000697	0.015	CbGpPWpGaD
Pomalidomide—PTGS2—Fluocinonide—Desonide—atopic dermatitis	0.000603	0.165	CbGdCrCtD
Pomalidomide—TNF—Cellular roles of Anthrax toxin—IL18—atopic dermatitis	0.000603	0.0129	CbGpPWpGaD
Pomalidomide—TNF—Death Receptor Signalling—CASP8—atopic dermatitis	0.000596	0.0128	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—IL17A—atopic dermatitis	0.000583	0.0125	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FOXP3—atopic dermatitis	0.000582	0.0125	CbGpPWpGaD
Pomalidomide—TNF—EBV LMP1 signaling—CCL5—atopic dermatitis	0.000582	0.0125	CbGpPWpGaD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—CASP1—atopic dermatitis	0.00056	0.012	CbGpPWpGaD
Pomalidomide—TNF—IL27-mediated signaling events—IL18—atopic dermatitis	0.000528	0.0113	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL10—atopic dermatitis	0.00051	0.0109	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL4—atopic dermatitis	0.000496	0.0106	CbGpPWpGaD
Pomalidomide—PTGS2—Fluocinonide—Fluocinolone Acetonide—atopic dermatitis	0.00047	0.128	CbGdCrCtD
Pomalidomide—TNF—RXR and RAR heterodimerization with other nuclear receptor—PPARA—atopic dermatitis	0.000456	0.00978	CbGpPWpGaD
Pomalidomide—TNF—Canonical NF-kappaB pathway—NFKBIA—atopic dermatitis	0.000445	0.00954	CbGpPWpGaD
Pomalidomide—TNF—EBV LMP1 signaling—NFKBIA—atopic dermatitis	0.000445	0.00954	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL5—atopic dermatitis	0.000426	0.00914	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—FOXP3—atopic dermatitis	0.000404	0.00866	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—IL18—atopic dermatitis	0.000398	0.00854	CbGpPWpGaD
Pomalidomide—PTGS2—Fluocinonide—Mometasone—atopic dermatitis	0.000375	0.102	CbGdCrCtD
Pomalidomide—TNF—Overview of nanoparticle effects—CXCL8—atopic dermatitis	0.000369	0.00793	CbGpPWpGaD
Pomalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—atopic dermatitis	0.000368	0.00789	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FOXP3—atopic dermatitis	0.00036	0.00773	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—CCL5—atopic dermatitis	0.00036	0.00772	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IL13—atopic dermatitis	0.000345	0.00741	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—SELE—atopic dermatitis	0.000345	0.00741	CbGpPWpGaD
Pomalidomide—TNF—HIV-1 Nef: Negative effector of Fas and TNF-alpha—NFKBIA—atopic dermatitis	0.000333	0.00715	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IL17A—atopic dermatitis	0.000318	0.00682	CbGpPWpGaD
Pomalidomide—TNF—EBV LMP1 signaling—CXCL8—atopic dermatitis	0.000317	0.0068	CbGpPWpGaD
Pomalidomide—TNF—Cellular roles of Anthrax toxin—IL1B—atopic dermatitis	0.000315	0.00676	CbGpPWpGaD
Pomalidomide—TNF—IL27-mediated signaling events—IFNG—atopic dermatitis	0.000309	0.00663	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—CCL5—atopic dermatitis	0.000308	0.00661	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—NFKBIA—atopic dermatitis	0.000304	0.00652	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—atopic dermatitis	0.000303	0.0065	CbGpPWpGaD
Pomalidomide—TNF—HIV-1 Nef: Negative effector of Fas and TNF-alpha—CASP8—atopic dermatitis	0.0003	0.00645	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IFNG—atopic dermatitis	0.0003	0.00644	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CASP1—atopic dermatitis	0.000297	0.00637	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IL5—atopic dermatitis	0.000295	0.00634	CbGpPWpGaD
Pomalidomide—PTGS2—Fluticasone Propionate—Fluocinonide—atopic dermatitis	0.000292	0.0797	CbGdCrCtD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—atopic dermatitis	0.00029	0.00622	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—CD4—atopic dermatitis	0.00029	0.00622	CbGpPWpGaD
Pomalidomide—TNF—Transcription factor regulation in adipogenesis—MAPK8—atopic dermatitis	0.000289	0.0062	CbGpPWpGaD
Pomalidomide—TNF—Type II diabetes mellitus—MAPK8—atopic dermatitis	0.000289	0.0062	CbGpPWpGaD
Pomalidomide—PTGS2—Fluticasone Propionate—Fluocinolone Acetonide—atopic dermatitis	0.000283	0.0774	CbGdCrCtD
Pomalidomide—TNF—EBV LMP1 signaling—MAPK8—atopic dermatitis	0.000279	0.00598	CbGpPWpGaD
Pomalidomide—CYP1A2—Estrogen Receptor Pathway—PPARA—atopic dermatitis	0.000278	0.00596	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—STAT6—atopic dermatitis	0.000276	0.00593	CbGpPWpGaD
Pomalidomide—TNF—IL27-mediated signaling events—IL1B—atopic dermatitis	0.000276	0.00592	CbGpPWpGaD
Pomalidomide—TNF—IL27-mediated signaling events—IL2—atopic dermatitis	0.000275	0.00589	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—NFKBIA—atopic dermatitis	0.000275	0.00589	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL1B—atopic dermatitis	0.000267	0.00574	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL2—atopic dermatitis	0.000266	0.00572	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL5—atopic dermatitis	0.000263	0.00565	CbGpPWpGaD
Pomalidomide—TNF—FAS pathway and Stress induction of HSP regulation—CASP8—atopic dermatitis	0.000248	0.00532	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—CASP8—atopic dermatitis	0.000248	0.00532	CbGpPWpGaD
Pomalidomide—TNF—Ceramide signaling pathway—NFKBIA—atopic dermatitis	0.000247	0.0053	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—CD8A—atopic dermatitis	0.000247	0.00529	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—IL4—atopic dermatitis	0.000243	0.00521	CbGpPWpGaD
Pomalidomide—TNF—Monoamine Transport—IL1B—atopic dermatitis	0.000234	0.00501	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—IFNG—atopic dermatitis	0.000233	0.005	CbGpPWpGaD
Pomalidomide—TNF—TNF receptor signaling pathway —CASP8—atopic dermatitis	0.00023	0.00494	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—TLR2—atopic dermatitis	0.00023	0.00493	CbGpPWpGaD
Pomalidomide—PTGS2—Overview of nanoparticle effects—CXCL8—atopic dermatitis	0.000228	0.0049	CbGpPWpGaD
Pomalidomide—PTGS2—Fluticasone Propionate—Mometasone—atopic dermatitis	0.000226	0.0618	CbGdCrCtD
Pomalidomide—TNF—IL23-mediated signaling events—CD4—atopic dermatitis	0.000225	0.00483	CbGpPWpGaD
Pomalidomide—PTGS2—Fluocinonide—Methylprednisolone—atopic dermatitis	0.000224	0.0612	CbGdCrCtD
Pomalidomide—TNF—Ceramide signaling pathway—CASP8—atopic dermatitis	0.000223	0.00478	CbGpPWpGaD
Pomalidomide—PTGS2—Fluocinonide—Dexamethasone—atopic dermatitis	0.00022	0.0602	CbGdCrCtD
Pomalidomide—PTGS2—Fluocinonide—Betamethasone—atopic dermatitis	0.00022	0.0602	CbGdCrCtD
Pomalidomide—TNF—Allograft Rejection—IL10—atopic dermatitis	0.000216	0.00464	CbGpPWpGaD
Pomalidomide—PTGS2—Fluocinonide—Triamcinolone—atopic dermatitis	0.000215	0.0588	CbGdCrCtD
Pomalidomide—TNF—Allograft Rejection—IL4—atopic dermatitis	0.00021	0.00451	CbGpPWpGaD
Pomalidomide—TNF—HIV-1 Nef: Negative effector of Fas and TNF-alpha—MAPK8—atopic dermatitis	0.000209	0.00448	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—IL1B—atopic dermatitis	0.000208	0.00446	CbGpPWpGaD
Pomalidomide—TNF—Overview of nanoparticle effects—IL6—atopic dermatitis	0.000207	0.00445	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—IL2—atopic dermatitis	0.000207	0.00444	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—CXCL10—atopic dermatitis	0.000205	0.00441	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL13—atopic dermatitis	0.0002	0.0043	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IFNG—atopic dermatitis	0.000196	0.0042	CbGpPWpGaD
Pomalidomide—TNF—Caspase Cascade in Apoptosis—CASP8—atopic dermatitis	0.000194	0.00416	CbGpPWpGaD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—PPARA—atopic dermatitis	0.000191	0.0041	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—atopic dermatitis	0.000187	0.00402	CbGpPWpGaD
Pomalidomide—TNF—Transcription factor regulation in adipogenesis—IL6—atopic dermatitis	0.000185	0.00396	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—TAC1—atopic dermatitis	0.000184	0.00396	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—atopic dermatitis	0.000183	0.00393	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—CXCL10—atopic dermatitis	0.000183	0.00392	CbGpPWpGaD
Pomalidomide—TNF—Signaling events mediated by HDAC Class I—NFKBIA—atopic dermatitis	0.000182	0.00392	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—IFNG—atopic dermatitis	0.00018	0.00387	CbGpPWpGaD
Pomalidomide—Bronchitis—Triamcinolone—atopic dermatitis	0.00018	0.00155	CcSEcCtD
Pomalidomide—Body temperature increased—Mometasone—atopic dermatitis	0.00018	0.00155	CcSEcCtD
Pomalidomide—Weight decreased—Hydrocortisone—atopic dermatitis	0.00018	0.00155	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—TLR2—atopic dermatitis	0.000179	0.00385	CbGpPWpGaD
Pomalidomide—Hypokalaemia—Betamethasone—atopic dermatitis	0.000179	0.00154	CcSEcCtD
Pomalidomide—Hypokalaemia—Dexamethasone—atopic dermatitis	0.000179	0.00154	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Prednisolone—atopic dermatitis	0.000178	0.00153	CcSEcCtD
Pomalidomide—Nervous system disorder—Tacrolimus—atopic dermatitis	0.000178	0.00153	CcSEcCtD
Pomalidomide—Thrombocytopenia—Tacrolimus—atopic dermatitis	0.000178	0.00153	CcSEcCtD
Pomalidomide—Infestation NOS—Hydrocortisone—atopic dermatitis	0.000177	0.00153	CcSEcCtD
Pomalidomide—Infestation—Hydrocortisone—atopic dermatitis	0.000177	0.00153	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—FOXP3—atopic dermatitis	0.000177	0.0038	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—CCL5—atopic dermatitis	0.000177	0.00379	CbGpPWpGaD
Pomalidomide—Skin disorder—Tacrolimus—atopic dermatitis	0.000176	0.00152	CcSEcCtD
Pomalidomide—Hypersensitivity—Fluocinolone Acetonide—atopic dermatitis	0.000176	0.00151	CcSEcCtD
Pomalidomide—Dizziness—Loratadine—atopic dermatitis	0.000176	0.00151	CcSEcCtD
Pomalidomide—Hyperhidrosis—Tacrolimus—atopic dermatitis	0.000175	0.00151	CcSEcCtD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—atopic dermatitis	0.000175	0.00376	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IL1B—atopic dermatitis	0.000175	0.00375	CbGpPWpGaD
Pomalidomide—Upper respiratory tract infection—Triamcinolone—atopic dermatitis	0.000174	0.0015	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IL2—atopic dermatitis	0.000174	0.00373	CbGpPWpGaD
Pomalidomide—Neuropathy peripheral—Hydrocortisone—atopic dermatitis	0.000174	0.0015	CcSEcCtD
Pomalidomide—Muscular weakness—Dexamethasone—atopic dermatitis	0.000173	0.00149	CcSEcCtD
Pomalidomide—Muscular weakness—Betamethasone—atopic dermatitis	0.000173	0.00149	CcSEcCtD
Pomalidomide—TNF—FAS pathway and Stress induction of HSP regulation—MAPK8—atopic dermatitis	0.000172	0.0037	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—MAPK8—atopic dermatitis	0.000172	0.0037	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—IFNG—atopic dermatitis	0.000172	0.0037	CbGpPWpGaD
Pomalidomide—Weight increased—Triamcinolone—atopic dermatitis	0.000171	0.00147	CcSEcCtD
Pomalidomide—TNF—MAPK Signaling Pathway—CASP1—atopic dermatitis	0.00017	0.00366	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—atopic dermatitis	0.00017	0.00366	CbGpPWpGaD
Pomalidomide—Weight increased—Methylprednisolone—atopic dermatitis	0.00017	0.00147	CcSEcCtD
Pomalidomide—Pruritus—Fluocinolone Acetonide—atopic dermatitis	0.000169	0.00145	CcSEcCtD
Pomalidomide—Vomiting—Loratadine—atopic dermatitis	0.000169	0.00145	CcSEcCtD
Pomalidomide—Rash—Loratadine—atopic dermatitis	0.000167	0.00144	CcSEcCtD
Pomalidomide—Dermatitis—Loratadine—atopic dermatitis	0.000167	0.00144	CcSEcCtD
Pomalidomide—Infestation—Methylprednisolone—atopic dermatitis	0.000167	0.00144	CcSEcCtD
Pomalidomide—Infestation NOS—Methylprednisolone—atopic dermatitis	0.000167	0.00144	CcSEcCtD
Pomalidomide—Headache—Loratadine—atopic dermatitis	0.000166	0.00143	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Tacrolimus—atopic dermatitis	0.000165	0.00142	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—BDNF—atopic dermatitis	0.000164	0.00352	CbGpPWpGaD
Pomalidomide—Insomnia—Tacrolimus—atopic dermatitis	0.000164	0.00141	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Triamcinolone—atopic dermatitis	0.000164	0.00141	CcSEcCtD
Pomalidomide—Asthenia—Mometasone—atopic dermatitis	0.000164	0.00141	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Methylprednisolone—atopic dermatitis	0.000163	0.00141	CcSEcCtD
Pomalidomide—Diarrhoea—Fluocinolone Acetonide—atopic dermatitis	0.000163	0.00141	CcSEcCtD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—atopic dermatitis	0.000163	0.00349	CbGpPWpGaD
Pomalidomide—Dyspnoea—Tacrolimus—atopic dermatitis	0.000162	0.00139	CcSEcCtD
Pomalidomide—TNF—IL27-mediated signaling events—IL6—atopic dermatitis	0.000161	0.00346	CbGpPWpGaD
Pomalidomide—Pruritus—Mometasone—atopic dermatitis	0.000161	0.00139	CcSEcCtD
Pomalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—atopic dermatitis	0.000161	0.00346	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—IL1B—atopic dermatitis	0.000161	0.00345	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—CXCL10—atopic dermatitis	0.00016	0.00344	CbGpPWpGaD
Pomalidomide—PTGS2—Overview of nanoparticle effects—TNF—atopic dermatitis	0.000159	0.00341	CbGpPWpGaD
Pomalidomide—Dizziness—Fluocinolone Acetonide—atopic dermatitis	0.000158	0.00136	CcSEcCtD
Pomalidomide—Nausea—Loratadine—atopic dermatitis	0.000158	0.00136	CcSEcCtD
Pomalidomide—TNF—Apoptosis—NFKBIA—atopic dermatitis	0.000158	0.00338	CbGpPWpGaD
Pomalidomide—Decreased appetite—Tacrolimus—atopic dermatitis	0.000158	0.00136	CcSEcCtD
Pomalidomide—Epistaxis—Triamcinolone—atopic dermatitis	0.000158	0.00136	CcSEcCtD
Pomalidomide—Dry skin—Prednisone—atopic dermatitis	0.000157	0.00135	CcSEcCtD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL6—atopic dermatitis	0.000157	0.00336	CbGpPWpGaD
Pomalidomide—Gastrointestinal disorder—Tacrolimus—atopic dermatitis	0.000157	0.00135	CcSEcCtD
Pomalidomide—Connective tissue disorder—Hydrocortisone—atopic dermatitis	0.000157	0.00135	CcSEcCtD
Pomalidomide—Fatigue—Tacrolimus—atopic dermatitis	0.000156	0.00135	CcSEcCtD
Pomalidomide—Diarrhoea—Mometasone—atopic dermatitis	0.000156	0.00134	CcSEcCtD
Pomalidomide—Hypokalaemia—Prednisone—atopic dermatitis	0.000156	0.00134	CcSEcCtD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—atopic dermatitis	0.000156	0.00334	CbGpPWpGaD
Pomalidomide—Pain—Tacrolimus—atopic dermatitis	0.000155	0.00134	CcSEcCtD
Pomalidomide—Constipation—Tacrolimus—atopic dermatitis	0.000155	0.00134	CcSEcCtD
Pomalidomide—TNF—Ceramide signaling pathway—MAPK8—atopic dermatitis	0.000155	0.00332	CbGpPWpGaD
Pomalidomide—Weight increased—Dexamethasone—atopic dermatitis	0.000155	0.00133	CcSEcCtD
Pomalidomide—Weight increased—Betamethasone—atopic dermatitis	0.000155	0.00133	CcSEcCtD
Pomalidomide—Weight decreased—Dexamethasone—atopic dermatitis	0.000154	0.00132	CcSEcCtD
Pomalidomide—Weight decreased—Betamethasone—atopic dermatitis	0.000154	0.00132	CcSEcCtD
Pomalidomide—Hyperglycaemia—Dexamethasone—atopic dermatitis	0.000153	0.00132	CcSEcCtD
Pomalidomide—Hyperglycaemia—Betamethasone—atopic dermatitis	0.000153	0.00132	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—IL4—atopic dermatitis	0.000152	0.00327	CbGpPWpGaD
Pomalidomide—Vomiting—Fluocinolone Acetonide—atopic dermatitis	0.000152	0.00131	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—IL13—atopic dermatitis	0.000151	0.00325	CbGpPWpGaD
Pomalidomide—Alanine aminotransferase increased—Prednisone—atopic dermatitis	0.000151	0.0013	CcSEcCtD
Pomalidomide—Muscular weakness—Prednisone—atopic dermatitis	0.000151	0.0013	CcSEcCtD
Pomalidomide—Rash—Fluocinolone Acetonide—atopic dermatitis	0.00015	0.0013	CcSEcCtD
Pomalidomide—Dermatitis—Fluocinolone Acetonide—atopic dermatitis	0.00015	0.0013	CcSEcCtD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—MAPK8—atopic dermatitis	0.00015	0.00322	CbGpPWpGaD
Pomalidomide—Headache—Fluocinolone Acetonide—atopic dermatitis	0.00015	0.00129	CcSEcCtD
Pomalidomide—Feeling abnormal—Tacrolimus—atopic dermatitis	0.000149	0.00129	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—CASP8—atopic dermatitis	0.000149	0.00321	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—CASP8—atopic dermatitis	0.000149	0.00321	CbGpPWpGaD
Pomalidomide—Neuropathy peripheral—Betamethasone—atopic dermatitis	0.000149	0.00128	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Dexamethasone—atopic dermatitis	0.000149	0.00128	CcSEcCtD
Pomalidomide—Connective tissue disorder—Methylprednisolone—atopic dermatitis	0.000147	0.00127	CcSEcCtD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IFNG—atopic dermatitis	0.000147	0.00315	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—IFNG—atopic dermatitis	0.000147	0.00315	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—NFKBIA—atopic dermatitis	0.000147	0.00315	CbGpPWpGaD
Pomalidomide—Vomiting—Mometasone—atopic dermatitis	0.000145	0.00125	CcSEcCtD
Pomalidomide—Rash—Mometasone—atopic dermatitis	0.000144	0.00124	CcSEcCtD
Pomalidomide—Dermatitis—Mometasone—atopic dermatitis	0.000144	0.00124	CcSEcCtD
Pomalidomide—Body temperature increased—Tacrolimus—atopic dermatitis	0.000143	0.00124	CcSEcCtD
Pomalidomide—Headache—Mometasone—atopic dermatitis	0.000143	0.00123	CcSEcCtD
Pomalidomide—TNF—Apoptosis—CASP8—atopic dermatitis	0.000142	0.00305	CbGpPWpGaD
Pomalidomide—Nausea—Fluocinolone Acetonide—atopic dermatitis	0.000142	0.00122	CcSEcCtD
Pomalidomide—Mental disorder—Hydrocortisone—atopic dermatitis	0.00014	0.0012	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—IL17A—atopic dermatitis	0.000139	0.00299	CbGpPWpGaD
Pomalidomide—Cardiac disorder—Methylprednisolone—atopic dermatitis	0.000139	0.0012	CcSEcCtD
Pomalidomide—TNF—Cardiac Hypertrophic Response—MAPK8—atopic dermatitis	0.000139	0.00298	CbGpPWpGaD
Pomalidomide—Malnutrition—Hydrocortisone—atopic dermatitis	0.000139	0.00119	CcSEcCtD
Pomalidomide—Neutropenia—Prednisone—atopic dermatitis	0.000138	0.00119	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—CCL5—atopic dermatitis	0.000138	0.00296	CbGpPWpGaD
Pomalidomide—TNF—amb2 Integrin signaling—IL6—atopic dermatitis	0.000137	0.00293	CbGpPWpGaD
Pomalidomide—Angiopathy—Methylprednisolone—atopic dermatitis	0.000136	0.00117	CcSEcCtD
Pomalidomide—Nausea—Mometasone—atopic dermatitis	0.000135	0.00117	CcSEcCtD
Pomalidomide—PTGS2—Fluticasone Propionate—Methylprednisolone—atopic dermatitis	0.000135	0.0369	CbGdCrCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—NFKBIA—atopic dermatitis	0.000135	0.0029	CbGpPWpGaD
Pomalidomide—Mediastinal disorder—Methylprednisolone—atopic dermatitis	0.000135	0.00116	CcSEcCtD
Pomalidomide—Weight increased—Prednisone—atopic dermatitis	0.000135	0.00116	CcSEcCtD
Pomalidomide—Weight decreased—Prednisone—atopic dermatitis	0.000134	0.00115	CcSEcCtD
Pomalidomide—Hypersensitivity—Tacrolimus—atopic dermatitis	0.000134	0.00115	CcSEcCtD
Pomalidomide—Hyperglycaemia—Prednisone—atopic dermatitis	0.000134	0.00115	CcSEcCtD
Pomalidomide—PTGS2—Fluticasone Propionate—Betamethasone—atopic dermatitis	0.000133	0.0363	CbGdCrCtD
Pomalidomide—PTGS2—Fluticasone Propionate—Dexamethasone—atopic dermatitis	0.000133	0.0363	CbGdCrCtD
Pomalidomide—TNF—TNF alpha Signaling Pathway—CASP8—atopic dermatitis	0.000132	0.00284	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—BDNF—atopic dermatitis	0.000131	0.00282	CbGpPWpGaD
Pomalidomide—Mental disorder—Methylprednisolone—atopic dermatitis	0.000131	0.00113	CcSEcCtD
Pomalidomide—TNF—Folate Metabolism—IL1B—atopic dermatitis	0.000131	0.00281	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IL2—atopic dermatitis	0.00013	0.0028	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—IL2—atopic dermatitis	0.00013	0.0028	CbGpPWpGaD
Pomalidomide—Malnutrition—Methylprednisolone—atopic dermatitis	0.00013	0.00112	CcSEcCtD
Pomalidomide—Asthenia—Tacrolimus—atopic dermatitis	0.00013	0.00112	CcSEcCtD
Pomalidomide—PTGS2—Fluticasone Propionate—Triamcinolone—atopic dermatitis	0.00013	0.0355	CbGdCrCtD
Pomalidomide—ABCB1—Allograft Rejection—IL5—atopic dermatitis	0.00013	0.00278	CbGpPWpGaD
Pomalidomide—Neuropathy peripheral—Prednisone—atopic dermatitis	0.000129	0.00111	CcSEcCtD
Pomalidomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—atopic dermatitis	0.000129	0.00276	CbGpPWpGaD
Pomalidomide—Pruritus—Tacrolimus—atopic dermatitis	0.000128	0.00111	CcSEcCtD
Pomalidomide—PTGS2—Overview of nanoparticle effects—IL6—atopic dermatitis	0.000128	0.00275	CbGpPWpGaD
Pomalidomide—Vertigo—Prednisolone—atopic dermatitis	0.000128	0.0011	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—IFNG—atopic dermatitis	0.000127	0.00273	CbGpPWpGaD
Pomalidomide—Back pain—Triamcinolone—atopic dermatitis	0.000126	0.00109	CcSEcCtD
Pomalidomide—TNF—Adipogenesis—PPARA—atopic dermatitis	0.000126	0.0027	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL10—atopic dermatitis	0.000125	0.00269	CbGpPWpGaD
Pomalidomide—Vertigo—Hydrocortisone—atopic dermatitis	0.000125	0.00107	CcSEcCtD
Pomalidomide—Diarrhoea—Tacrolimus—atopic dermatitis	0.000124	0.00107	CcSEcCtD
Pomalidomide—TNF—MAPK Signaling Pathway—BDNF—atopic dermatitis	0.000124	0.00266	CbGpPWpGaD
Pomalidomide—Angiopathy—Dexamethasone—atopic dermatitis	0.000123	0.00106	CcSEcCtD
Pomalidomide—Angiopathy—Betamethasone—atopic dermatitis	0.000123	0.00106	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—CASP8—atopic dermatitis	0.000122	0.00261	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—IL6—atopic dermatitis	0.000122	0.00261	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—MAPK8—atopic dermatitis	0.00012	0.00258	CbGpPWpGaD
Pomalidomide—Dizziness—Tacrolimus—atopic dermatitis	0.00012	0.00103	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—CXCL8—atopic dermatitis	0.000118	0.00254	CbGpPWpGaD
Pomalidomide—Anxiety—Hydrocortisone—atopic dermatitis	0.000118	0.00101	CcSEcCtD
Pomalidomide—Vertigo—Triamcinolone—atopic dermatitis	0.000117	0.00101	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—atopic dermatitis	0.000117	0.00101	CcSEcCtD
Pomalidomide—Vertigo—Methylprednisolone—atopic dermatitis	0.000117	0.00101	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—NGF—atopic dermatitis	0.000117	0.0025	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—IFNG—atopic dermatitis	0.000117	0.0025	CbGpPWpGaD
Pomalidomide—Connective tissue disorder—Prednisone—atopic dermatitis	0.000116	0.001	CcSEcCtD
Pomalidomide—Vomiting—Tacrolimus—atopic dermatitis	0.000115	0.000993	CcSEcCtD
Pomalidomide—Rash—Tacrolimus—atopic dermatitis	0.000114	0.000985	CcSEcCtD
Pomalidomide—Dermatitis—Tacrolimus—atopic dermatitis	0.000114	0.000984	CcSEcCtD
Pomalidomide—Cough—Triamcinolone—atopic dermatitis	0.000114	0.000981	CcSEcCtD
Pomalidomide—Headache—Tacrolimus—atopic dermatitis	0.000114	0.000979	CcSEcCtD
Pomalidomide—TNF—Alzheimers Disease—IL1B—atopic dermatitis	0.000113	0.00243	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IL1B—atopic dermatitis	0.000113	0.00243	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—atopic dermatitis	0.000113	0.00243	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CXCL10—atopic dermatitis	0.000113	0.00243	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IL2—atopic dermatitis	0.000113	0.00242	CbGpPWpGaD
Pomalidomide—Infection—Hydrocortisone—atopic dermatitis	0.000112	0.000968	CcSEcCtD
Pomalidomide—Hyperhidrosis—Prednisolone—atopic dermatitis	0.000112	0.000965	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—BDNF—atopic dermatitis	0.000112	0.0024	CbGpPWpGaD
Pomalidomide—Nervous system disorder—Hydrocortisone—atopic dermatitis	0.000111	0.000956	CcSEcCtD
Pomalidomide—Arthralgia—Methylprednisolone—atopic dermatitis	0.000111	0.000955	CcSEcCtD
Pomalidomide—Anxiety—Methylprednisolone—atopic dermatitis	0.000111	0.000952	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—atopic dermatitis	0.00011	0.000949	CcSEcCtD
Pomalidomide—TNF—TWEAK Signaling Pathway—IL6—atopic dermatitis	0.00011	0.00236	CbGpPWpGaD
Pomalidomide—Skin disorder—Hydrocortisone—atopic dermatitis	0.00011	0.000947	CcSEcCtD
Pomalidomide—TNF—MAPK Signaling Pathway—NGF—atopic dermatitis	0.00011	0.00236	CbGpPWpGaD
Pomalidomide—Hyperhidrosis—Hydrocortisone—atopic dermatitis	0.000109	0.000942	CcSEcCtD
Pomalidomide—Nausea—Tacrolimus—atopic dermatitis	0.000108	0.000928	CcSEcCtD
Pomalidomide—Angiopathy—Prednisone—atopic dermatitis	0.000108	0.000926	CcSEcCtD
Pomalidomide—Confusional state—Methylprednisolone—atopic dermatitis	0.000107	0.000923	CcSEcCtD
Pomalidomide—Vertigo—Dexamethasone—atopic dermatitis	0.000106	0.000917	CcSEcCtD
Pomalidomide—Vertigo—Betamethasone—atopic dermatitis	0.000106	0.000917	CcSEcCtD
Pomalidomide—Infection—Triamcinolone—atopic dermatitis	0.000106	0.000912	CcSEcCtD
Pomalidomide—Infection—Methylprednisolone—atopic dermatitis	0.000106	0.00091	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—NFKBIA—atopic dermatitis	0.000105	0.00226	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—atopic dermatitis	0.000105	0.00226	CbGpPWpGaD
Pomalidomide—Insomnia—Prednisolone—atopic dermatitis	0.000105	0.000903	CcSEcCtD
Pomalidomide—Nervous system disorder—Methylprednisolone—atopic dermatitis	0.000104	0.000898	CcSEcCtD
Pomalidomide—TNF—Selenium Micronutrient Network—IL1B—atopic dermatitis	0.000104	0.00223	CbGpPWpGaD
Pomalidomide—Mental disorder—Prednisone—atopic dermatitis	0.000104	0.000894	CcSEcCtD
Pomalidomide—Skin disorder—Methylprednisolone—atopic dermatitis	0.000103	0.000889	CcSEcCtD
Pomalidomide—Malnutrition—Prednisone—atopic dermatitis	0.000103	0.000889	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Hydrocortisone—atopic dermatitis	0.000103	0.000888	CcSEcCtD
Pomalidomide—Hyperhidrosis—Triamcinolone—atopic dermatitis	0.000103	0.000887	CcSEcCtD
Pomalidomide—Hyperhidrosis—Methylprednisolone—atopic dermatitis	0.000103	0.000885	CcSEcCtD
Pomalidomide—Insomnia—Hydrocortisone—atopic dermatitis	0.000102	0.000882	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—BDNF—atopic dermatitis	0.000102	0.00218	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—atopic dermatitis	0.000101	0.00216	CbGpPWpGaD
Pomalidomide—Anxiety—Dexamethasone—atopic dermatitis	0.000101	0.000866	CcSEcCtD
Pomalidomide—Anxiety—Betamethasone—atopic dermatitis	0.000101	0.000866	CcSEcCtD
Pomalidomide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—atopic dermatitis	9.93e-05	0.00213	CbGpPWpGaD
Pomalidomide—Pain—Prednisolone—atopic dermatitis	9.91e-05	0.000853	CcSEcCtD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—MAPK8—atopic dermatitis	9.89e-05	0.00212	CbGpPWpGaD
Pomalidomide—Decreased appetite—Hydrocortisone—atopic dermatitis	9.84e-05	0.000847	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Hydrocortisone—atopic dermatitis	9.77e-05	0.000841	CcSEcCtD
Pomalidomide—Fatigue—Hydrocortisone—atopic dermatitis	9.76e-05	0.00084	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Triamcinolone—atopic dermatitis	9.71e-05	0.000836	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Methylprednisolone—atopic dermatitis	9.69e-05	0.000834	CcSEcCtD
Pomalidomide—Pain—Hydrocortisone—atopic dermatitis	9.68e-05	0.000833	CcSEcCtD
Pomalidomide—Insomnia—Triamcinolone—atopic dermatitis	9.64e-05	0.00083	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—CXCL8—atopic dermatitis	9.63e-05	0.00207	CbGpPWpGaD
Pomalidomide—Insomnia—Methylprednisolone—atopic dermatitis	9.62e-05	0.000828	CcSEcCtD
Pomalidomide—Infection—Betamethasone—atopic dermatitis	9.6e-05	0.000827	CcSEcCtD
Pomalidomide—Infection—Dexamethasone—atopic dermatitis	9.6e-05	0.000827	CcSEcCtD
Pomalidomide—Feeling abnormal—Prednisolone—atopic dermatitis	9.55e-05	0.000822	CcSEcCtD
Pomalidomide—Anaemia—Prednisone—atopic dermatitis	9.54e-05	0.000821	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—CASP8—atopic dermatitis	9.51e-05	0.00204	CbGpPWpGaD
Pomalidomide—Dyspnoea—Triamcinolone—atopic dermatitis	9.5e-05	0.000818	CcSEcCtD
Pomalidomide—Nervous system disorder—Betamethasone—atopic dermatitis	9.48e-05	0.000817	CcSEcCtD
Pomalidomide—Nervous system disorder—Dexamethasone—atopic dermatitis	9.48e-05	0.000817	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—IL10—atopic dermatitis	9.47e-05	0.00203	CbGpPWpGaD
Pomalidomide—Thrombocytopenia—Dexamethasone—atopic dermatitis	9.47e-05	0.000815	CcSEcCtD
Pomalidomide—Thrombocytopenia—Betamethasone—atopic dermatitis	9.47e-05	0.000815	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—IL4—atopic dermatitis	9.43e-05	0.00202	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—IL6—atopic dermatitis	9.42e-05	0.00202	CbGpPWpGaD
Pomalidomide—Hyperhidrosis—Dexamethasone—atopic dermatitis	9.35e-05	0.000805	CcSEcCtD
Pomalidomide—Hyperhidrosis—Betamethasone—atopic dermatitis	9.35e-05	0.000805	CcSEcCtD
Pomalidomide—Feeling abnormal—Hydrocortisone—atopic dermatitis	9.33e-05	0.000803	CcSEcCtD
Pomalidomide—Vertigo—Prednisone—atopic dermatitis	9.27e-05	0.000798	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—IL1B—atopic dermatitis	9.24e-05	0.00198	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IFNG—atopic dermatitis	9.22e-05	0.00198	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL4—atopic dermatitis	9.21e-05	0.00198	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—MAPK8—atopic dermatitis	9.2e-05	0.00197	CbGpPWpGaD
Pomalidomide—Fatigue—Triamcinolone—atopic dermatitis	9.19e-05	0.000791	CcSEcCtD
Pomalidomide—Fatigue—Methylprednisolone—atopic dermatitis	9.17e-05	0.000789	CcSEcCtD
Pomalidomide—Pain—Triamcinolone—atopic dermatitis	9.11e-05	0.000785	CcSEcCtD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—TRPV3—atopic dermatitis	9.05e-05	0.00194	CbGpPWpGaD
Pomalidomide—Body temperature increased—Hydrocortisone—atopic dermatitis	8.95e-05	0.00077	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Dexamethasone—atopic dermatitis	8.81e-05	0.000759	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Betamethasone—atopic dermatitis	8.81e-05	0.000759	CcSEcCtD
Pomalidomide—Arthralgia—Prednisone—atopic dermatitis	8.78e-05	0.000756	CcSEcCtD
Pomalidomide—Feeling abnormal—Triamcinolone—atopic dermatitis	8.78e-05	0.000756	CcSEcCtD
Pomalidomide—Feeling abnormal—Methylprednisolone—atopic dermatitis	8.76e-05	0.000755	CcSEcCtD
Pomalidomide—Anxiety—Prednisone—atopic dermatitis	8.75e-05	0.000754	CcSEcCtD
Pomalidomide—Insomnia—Dexamethasone—atopic dermatitis	8.74e-05	0.000753	CcSEcCtD
Pomalidomide—Insomnia—Betamethasone—atopic dermatitis	8.74e-05	0.000753	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—atopic dermatitis	8.72e-05	0.000751	CcSEcCtD
Pomalidomide—TNF—Apoptosis—CASP8—atopic dermatitis	8.71e-05	0.00187	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—CXCL8—atopic dermatitis	8.57e-05	0.00184	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Prednisolone—atopic dermatitis	8.54e-05	0.000735	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—MAPK8—atopic dermatitis	8.47e-05	0.00182	CbGpPWpGaD
Pomalidomide—Body temperature increased—Triamcinolone—atopic dermatitis	8.42e-05	0.000725	CcSEcCtD
Pomalidomide—Decreased appetite—Dexamethasone—atopic dermatitis	8.4e-05	0.000724	CcSEcCtD
Pomalidomide—Decreased appetite—Betamethasone—atopic dermatitis	8.4e-05	0.000724	CcSEcCtD
Pomalidomide—Infection—Prednisone—atopic dermatitis	8.36e-05	0.00072	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Dexamethasone—atopic dermatitis	8.35e-05	0.000719	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Betamethasone—atopic dermatitis	8.35e-05	0.000719	CcSEcCtD
Pomalidomide—Hypersensitivity—Hydrocortisone—atopic dermatitis	8.34e-05	0.000718	CcSEcCtD
Pomalidomide—Fatigue—Dexamethasone—atopic dermatitis	8.34e-05	0.000718	CcSEcCtD
Pomalidomide—Fatigue—Betamethasone—atopic dermatitis	8.34e-05	0.000718	CcSEcCtD
Pomalidomide—Pain—Betamethasone—atopic dermatitis	8.27e-05	0.000712	CcSEcCtD
Pomalidomide—Pain—Dexamethasone—atopic dermatitis	8.27e-05	0.000712	CcSEcCtD
Pomalidomide—Nervous system disorder—Prednisone—atopic dermatitis	8.26e-05	0.000711	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—IL1B—atopic dermatitis	8.22e-05	0.00176	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL2—atopic dermatitis	8.19e-05	0.00176	CbGpPWpGaD
Pomalidomide—Skin disorder—Prednisone—atopic dermatitis	8.18e-05	0.000704	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—NFKBIA—atopic dermatitis	8.17e-05	0.00175	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—CASP8—atopic dermatitis	8.17e-05	0.00175	CbGpPWpGaD
Pomalidomide—Hyperhidrosis—Prednisone—atopic dermatitis	8.14e-05	0.000701	CcSEcCtD
Pomalidomide—Asthenia—Hydrocortisone—atopic dermatitis	8.12e-05	0.000699	CcSEcCtD
Pomalidomide—Pruritus—Hydrocortisone—atopic dermatitis	8.01e-05	0.00069	CcSEcCtD
Pomalidomide—Feeling abnormal—Betamethasone—atopic dermatitis	7.97e-05	0.000686	CcSEcCtD
Pomalidomide—Feeling abnormal—Dexamethasone—atopic dermatitis	7.97e-05	0.000686	CcSEcCtD
Pomalidomide—Hypersensitivity—Triamcinolone—atopic dermatitis	7.85e-05	0.000676	CcSEcCtD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—atopic dermatitis	7.84e-05	0.00168	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Methylprednisolone—atopic dermatitis	7.83e-05	0.000675	CcSEcCtD
Pomalidomide—Diarrhoea—Hydrocortisone—atopic dermatitis	7.74e-05	0.000667	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Prednisone—atopic dermatitis	7.67e-05	0.000661	CcSEcCtD
Pomalidomide—TNF—Folate Metabolism—IL6—atopic dermatitis	7.66e-05	0.00164	CbGpPWpGaD
Pomalidomide—Dizziness—Prednisolone—atopic dermatitis	7.66e-05	0.00066	CcSEcCtD
Pomalidomide—Asthenia—Triamcinolone—atopic dermatitis	7.64e-05	0.000658	CcSEcCtD
Pomalidomide—Body temperature increased—Dexamethasone—atopic dermatitis	7.64e-05	0.000658	CcSEcCtD
Pomalidomide—Body temperature increased—Betamethasone—atopic dermatitis	7.64e-05	0.000658	CcSEcCtD
Pomalidomide—Asthenia—Methylprednisolone—atopic dermatitis	7.63e-05	0.000657	CcSEcCtD
Pomalidomide—Insomnia—Prednisone—atopic dermatitis	7.62e-05	0.000656	CcSEcCtD
Pomalidomide—Pruritus—Triamcinolone—atopic dermatitis	7.54e-05	0.000649	CcSEcCtD
Pomalidomide—Pruritus—Methylprednisolone—atopic dermatitis	7.52e-05	0.000648	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—CXCL8—atopic dermatitis	7.52e-05	0.00161	CbGpPWpGaD
Pomalidomide—Dizziness—Hydrocortisone—atopic dermatitis	7.48e-05	0.000645	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CASP8—atopic dermatitis	7.37e-05	0.00158	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—GLB1—atopic dermatitis	7.36e-05	0.00158	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—atopic dermatitis	7.33e-05	0.00157	CbGpPWpGaD
Pomalidomide—Decreased appetite—Prednisone—atopic dermatitis	7.32e-05	0.00063	CcSEcCtD
Pomalidomide—Rash—Prednisolone—atopic dermatitis	7.31e-05	0.000629	CcSEcCtD
Pomalidomide—Dermatitis—Prednisolone—atopic dermatitis	7.3e-05	0.000629	CcSEcCtD
Pomalidomide—Diarrhoea—Methylprednisolone—atopic dermatitis	7.27e-05	0.000627	CcSEcCtD
Pomalidomide—Fatigue—Prednisone—atopic dermatitis	7.26e-05	0.000625	CcSEcCtD
Pomalidomide—Headache—Prednisolone—atopic dermatitis	7.26e-05	0.000625	CcSEcCtD
Pomalidomide—PTGS2—C-MYB transcription factor network—CD4—atopic dermatitis	7.22e-05	0.00155	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL1B—atopic dermatitis	7.21e-05	0.00155	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IFNG—atopic dermatitis	7.21e-05	0.00155	CbGpPWpGaD
Pomalidomide—Constipation—Prednisone—atopic dermatitis	7.2e-05	0.00062	CcSEcCtD
Pomalidomide—Vomiting—Hydrocortisone—atopic dermatitis	7.19e-05	0.00062	CcSEcCtD
Pomalidomide—Rash—Hydrocortisone—atopic dermatitis	7.14e-05	0.000615	CcSEcCtD
Pomalidomide—Dermatitis—Hydrocortisone—atopic dermatitis	7.13e-05	0.000614	CcSEcCtD
Pomalidomide—Headache—Hydrocortisone—atopic dermatitis	7.09e-05	0.000611	CcSEcCtD
Pomalidomide—Dizziness—Triamcinolone—atopic dermatitis	7.05e-05	0.000607	CcSEcCtD
Pomalidomide—Dizziness—Methylprednisolone—atopic dermatitis	7.03e-05	0.000606	CcSEcCtD
Pomalidomide—Feeling abnormal—Prednisone—atopic dermatitis	6.94e-05	0.000598	CcSEcCtD
Pomalidomide—Asthenia—Dexamethasone—atopic dermatitis	6.94e-05	0.000597	CcSEcCtD
Pomalidomide—Asthenia—Betamethasone—atopic dermatitis	6.94e-05	0.000597	CcSEcCtD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—atopic dermatitis	6.91e-05	0.00148	CbGpPWpGaD
Pomalidomide—Nausea—Prednisolone—atopic dermatitis	6.88e-05	0.000593	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—CXCL8—atopic dermatitis	6.85e-05	0.00147	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—atopic dermatitis	6.85e-05	0.00147	CbGpPWpGaD
Pomalidomide—Pruritus—Dexamethasone—atopic dermatitis	6.84e-05	0.000589	CcSEcCtD
Pomalidomide—Pruritus—Betamethasone—atopic dermatitis	6.84e-05	0.000589	CcSEcCtD
Pomalidomide—Vomiting—Triamcinolone—atopic dermatitis	6.77e-05	0.000584	CcSEcCtD
Pomalidomide—Vomiting—Methylprednisolone—atopic dermatitis	6.76e-05	0.000582	CcSEcCtD
Pomalidomide—Nausea—Hydrocortisone—atopic dermatitis	6.72e-05	0.000579	CcSEcCtD
Pomalidomide—Rash—Triamcinolone—atopic dermatitis	6.72e-05	0.000579	CcSEcCtD
Pomalidomide—Dermatitis—Triamcinolone—atopic dermatitis	6.71e-05	0.000578	CcSEcCtD
Pomalidomide—Rash—Methylprednisolone—atopic dermatitis	6.7e-05	0.000577	CcSEcCtD
Pomalidomide—Dermatitis—Methylprednisolone—atopic dermatitis	6.7e-05	0.000577	CcSEcCtD
Pomalidomide—Headache—Triamcinolone—atopic dermatitis	6.68e-05	0.000575	CcSEcCtD
Pomalidomide—Headache—Methylprednisolone—atopic dermatitis	6.66e-05	0.000574	CcSEcCtD
Pomalidomide—Body temperature increased—Prednisone—atopic dermatitis	6.66e-05	0.000573	CcSEcCtD
Pomalidomide—Diarrhoea—Betamethasone—atopic dermatitis	6.62e-05	0.00057	CcSEcCtD
Pomalidomide—Diarrhoea—Dexamethasone—atopic dermatitis	6.62e-05	0.00057	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—MAPK8—atopic dermatitis	6.61e-05	0.00142	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL1B—atopic dermatitis	6.58e-05	0.00141	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CASP8—atopic dermatitis	6.55e-05	0.00141	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IL1B—atopic dermatitis	6.43e-05	0.00138	CbGpPWpGaD
Pomalidomide—Dizziness—Dexamethasone—atopic dermatitis	6.39e-05	0.000551	CcSEcCtD
Pomalidomide—Dizziness—Betamethasone—atopic dermatitis	6.39e-05	0.000551	CcSEcCtD
Pomalidomide—Nausea—Triamcinolone—atopic dermatitis	6.33e-05	0.000545	CcSEcCtD
Pomalidomide—Nausea—Methylprednisolone—atopic dermatitis	6.32e-05	0.000544	CcSEcCtD
Pomalidomide—Hypersensitivity—Prednisone—atopic dermatitis	6.2e-05	0.000534	CcSEcCtD
Pomalidomide—TNF—MAPK Signaling Pathway—IL1B—atopic dermatitis	6.2e-05	0.00133	CbGpPWpGaD
Pomalidomide—Vomiting—Dexamethasone—atopic dermatitis	6.15e-05	0.000529	CcSEcCtD
Pomalidomide—Vomiting—Betamethasone—atopic dermatitis	6.15e-05	0.000529	CcSEcCtD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—atopic dermatitis	6.11e-05	0.00131	CbGpPWpGaD
Pomalidomide—Rash—Dexamethasone—atopic dermatitis	6.1e-05	0.000525	CcSEcCtD
Pomalidomide—Rash—Betamethasone—atopic dermatitis	6.1e-05	0.000525	CcSEcCtD
Pomalidomide—Dermatitis—Betamethasone—atopic dermatitis	6.09e-05	0.000525	CcSEcCtD
Pomalidomide—Dermatitis—Dexamethasone—atopic dermatitis	6.09e-05	0.000525	CcSEcCtD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—atopic dermatitis	6.09e-05	0.00131	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—IL6—atopic dermatitis	6.09e-05	0.00131	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—MAPK8—atopic dermatitis	6.06e-05	0.0013	CbGpPWpGaD
Pomalidomide—Headache—Dexamethasone—atopic dermatitis	6.06e-05	0.000522	CcSEcCtD
Pomalidomide—Headache—Betamethasone—atopic dermatitis	6.06e-05	0.000522	CcSEcCtD
Pomalidomide—Asthenia—Prednisone—atopic dermatitis	6.04e-05	0.00052	CcSEcCtD
Pomalidomide—Pruritus—Prednisone—atopic dermatitis	5.96e-05	0.000513	CcSEcCtD
Pomalidomide—TNF—TNF alpha Signaling Pathway—IL6—atopic dermatitis	5.87e-05	0.00126	CbGpPWpGaD
Pomalidomide—Diarrhoea—Prednisone—atopic dermatitis	5.76e-05	0.000496	CcSEcCtD
Pomalidomide—Nausea—Betamethasone—atopic dermatitis	5.74e-05	0.000495	CcSEcCtD
Pomalidomide—Nausea—Dexamethasone—atopic dermatitis	5.74e-05	0.000495	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—IFNG—atopic dermatitis	5.7e-05	0.00122	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—MAPK8—atopic dermatitis	5.68e-05	0.00122	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IFNG—atopic dermatitis	5.57e-05	0.0012	CbGpPWpGaD
Pomalidomide—Dizziness—Prednisone—atopic dermatitis	5.57e-05	0.00048	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—IL6—atopic dermatitis	5.41e-05	0.00116	CbGpPWpGaD
Pomalidomide—Vomiting—Prednisone—atopic dermatitis	5.35e-05	0.000461	CcSEcCtD
Pomalidomide—Rash—Prednisone—atopic dermatitis	5.31e-05	0.000457	CcSEcCtD
Pomalidomide—Dermatitis—Prednisone—atopic dermatitis	5.3e-05	0.000457	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—CXCL8—atopic dermatitis	5.3e-05	0.00114	CbGpPWpGaD
Pomalidomide—Headache—Prednisone—atopic dermatitis	5.27e-05	0.000454	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—CXCL8—atopic dermatitis	5.18e-05	0.00111	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	5.13e-05	0.0011	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL1B—atopic dermatitis	5.08e-05	0.00109	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL2—atopic dermatitis	5.06e-05	0.00109	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—atopic dermatitis	5.06e-05	0.00108	CbGpPWpGaD
Pomalidomide—Nausea—Prednisone—atopic dermatitis	5e-05	0.000431	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—IL1B—atopic dermatitis	4.97e-05	0.00107	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL2—atopic dermatitis	4.95e-05	0.00106	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—atopic dermatitis	4.9e-05	0.00105	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL6—atopic dermatitis	4.81e-05	0.00103	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—TNF—atopic dermatitis	4.66e-05	0.001	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP8—atopic dermatitis	4.56e-05	0.000979	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—IL6—atopic dermatitis	4.45e-05	0.000956	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—atopic dermatitis	4.44e-05	0.000952	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—atopic dermatitis	4.44e-05	0.000952	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—PPARA—atopic dermatitis	4.32e-05	0.000928	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL6—atopic dermatitis	4.22e-05	0.000906	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—GLB1—atopic dermatitis	4.16e-05	0.000893	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—GLB1—atopic dermatitis	3.91e-05	0.00084	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL6—atopic dermatitis	3.85e-05	0.000826	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IL6—atopic dermatitis	3.76e-05	0.000808	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TNF—atopic dermatitis	3.69e-05	0.000792	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—TNF—atopic dermatitis	3.6e-05	0.000774	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—atopic dermatitis	3.58e-05	0.000769	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	3.32e-05	0.000713	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GLB1—atopic dermatitis	3.28e-05	0.000703	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—atopic dermatitis	3.23e-05	0.000694	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	3.17e-05	0.000681	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ADSL—atopic dermatitis	3.14e-05	0.000674	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL6—atopic dermatitis	2.98e-05	0.000639	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SLC11A1—atopic dermatitis	2.62e-05	0.000562	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	2.51e-05	0.000539	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	2.39e-05	0.000512	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GLB1—atopic dermatitis	2.32e-05	0.000498	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	2.25e-05	0.000482	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ADSL—atopic dermatitis	2.23e-05	0.000478	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GLB1—atopic dermatitis	1.85e-05	0.000398	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	1.78e-05	0.000382	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ADSL—atopic dermatitis	1.78e-05	0.000381	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—PPARA—atopic dermatitis	1.61e-05	0.000345	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—IL6—atopic dermatitis	1.53e-05	0.000329	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GLB1—atopic dermatitis	1.43e-05	0.000307	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ADSL—atopic dermatitis	1.37e-05	0.000294	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	1.35e-05	0.00029	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CCR5—atopic dermatitis	1.32e-05	0.000284	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PPARA—atopic dermatitis	1.06e-05	0.000228	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CD4—atopic dermatitis	8.32e-06	0.000178	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PPARA—atopic dermatitis	7.54e-06	0.000162	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PPARA—atopic dermatitis	6.02e-06	0.000129	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PPARA—atopic dermatitis	4.64e-06	9.97e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—IL6—atopic dermatitis	4.5e-06	9.65e-05	CbGpPWpGaD
